| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56b11188f223710057739fa8dd37776e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c930c1a3fcc9a93dc304ab4a77bd0ea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33643eaac90bc60096581a3baa113c4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c0e91dd32bf8f6c67093011cbd5d0c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded9c959d39800f9192084a6efcdbc3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_313fd057c78a96f229f4db02cb7e11ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6082e9107875d2f980d2a1e1fb34756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91b433e3c05da0444ffca1472382e25d |
| publicationDate |
2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2743950-T3 |
| titleOfInvention |
Human monoclonal antibodies against type 1 orexin receptor |
| abstract |
A human monoclonal antibody against OX1R comprising a heavy chain comprising i) HCDR1 from C2, ii) H-CDR2 from C2 and iii) H-CDR3 from C2 and a light chain comprising i) L-CDR1 from C2, ii) the L-CDR2 of C2 and iii) the L-CDR3 of C2, wherein - the H-CDR1 of C2 is defined by the sequence extending from the amino acid residue at position 31 to the residue of amino acid at position 35 in SEQ ID NO: 1, - C2 H-CDR2 is defined by the sequence that extends from the amino acid residue at position 50 to the amino acid residue at position 66 in SEQ ID NO: 1, - the H-CDR3 of C2 is defined by the sequence that extends from the amino acid residue at position 99 to the amino acid residue at position 109 in SEQ ID NO: 1, - the L-CDR1 of C2 is defined by the sequence extending from the amino acid residue at position 23 to the amino acid residue at position 36 in SEQ ID NO: 2, - the L-CDR2 of C2 is defined by the sequence extending from the amino acid residue at position 52 to the amino acid residue at position 58 in SEQ ID NO: 2, and - the L-CDR3 of C2 is defined by the sequence extending from the amino acid residue at position 91 to the amino acid residue at position 100 in SEQ ID NO: 2. |
| priorityDate |
2015-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |